Molecular Biology and Genetics Core
分子生物学和遗传学核心
基本信息
- 批准号:10094242
- 负责人:
- 金额:$ 22.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-02-05 至 2021-04-30
- 项目状态:已结题
- 来源:
- 关键词:AcetylationAcute Lung InjuryAdult Respiratory Distress SyndromeAfricanBiological AssayBiotechnologyCandidate Disease GeneDNADNA MethylationDNA-Protein InteractionData AnalysesDevelopmentElectrophoretic Mobility Shift AssayEndothelial CellsEpigenetic ProcessEscherichia coliEuropeanGene TargetingGenerationsGenesGeneticGenetic TranscriptionGenetic studyGenotypeHistone AcetylationInfrastructureInvestigationLaboratoriesLuciferasesLungMammalian CellMethodsMolecular BiologyMolecular GeneticsMusMutateMutationPatientsPost-Translational Protein ProcessingPredispositionProteinsReceptor SignalingRecombinant ProteinsRegulationReporterResearch PersonnelRoleSOX18 geneServicesSeveritiesSingle Nucleotide PolymorphismSite-Directed MutagenesisSphingosine-1-Phosphate ReceptorSystemTLR4 geneTechnologyTestingValidationVentilator-induced lung injurybiobankchromatin immunoprecipitationexperimental groupgenetic analysisinsightinterestnoveloverexpressionplasmid DNApromoterprotein functiontooltranslational impact
项目摘要
ABSTRACT:
This Molecular Biology & Genetics Core (Core B) will provide essential, cutting edge, molecular biology and
genetics expertise to facilitate the translational impact of this highly integrated PPG focused on ventilator-
induced lung injury (VILI) / acute respiratory distress syndrome (ARDS). PPG Core B will be responsible for
the generation of promoter luciferase reporter constructs, as well as modified promoter luciferase reporter
constructs (serially deleted or point mutated). Core B will also generate expression DNA plasmids for key
proteins studies in all three Projects for different over-expression systems including the E. Coli. system (for
Core D to generate recombinant protein), mammalian cell system (for projects to study protein function in
endothelial cells or murine lung delivery). We will also perform site-directed mutagenesis (SDM) on these
expression constructs to introduce mutations representing prioritized single nucleotide polymorphisms (SNPs)
or post-translational modifications (PTMs) of interest. Core B will also provide epigenetic analysis on DNA
methylation and acetylation with routine molecular biology methods. As a validation step, Core B will perform
DNA-protein interaction characterizations utilizing electrophoretic mobility shift assay (EMSA) and chromatin
immunoprecipitation (ChIP). In addition, Core B will provide Project investigators with a well-characterized
ARDS biobank (i.e. DNA from European descent and African descent subjects), a complete list of selected
SNPs for each PPG candidate gene, mid-throughput genotyping services, and data analysis tools to test the
association between PPG selected SNPs and susceptibility and severity of VILI/ARDS. Thus, overall Core B
will utilize these technologies to provide a molecular biology and genetics study platform for all three Projects
and generate novel information on the genes targeted for investigation in this PPG. All three Projects and
Core D will utilize this centralized core for the molecular biology and genetics analyses planned in this PPG.
摘要:
这个分子生物学和遗传学核心(核心B)将提供基本的、尖端的、分子生物学和
遗传学专业知识,以促进这一高度集成的PPG专注于呼吸机的翻译影响-
诱发肺损伤(VILI)/急性呼吸窘迫综合征(ARDS)。PPG Core B将负责
启动子荧光素酶报告基因的生成及其修饰的启动子荧光素酶报告基因的构建
构造(连续删除或点突变)。核心B还将为KEY生成表达DNA质粒
在所有三个项目中对不同过度表达系统的蛋白质进行研究,包括E.Coli。系统(用于
核心D产生重组蛋白),哺乳动物细胞系统(用于研究蛋白质功能的项目
内皮细胞或小鼠肺递送)。我们还将对这些基因进行定点突变(SDM)
表达载体引入代表优先单核苷酸多态(SNPs)的突变
或感兴趣的翻译后修饰(PTM)。核心B还将提供DNA的表观遗传学分析
用常规的分子生物学方法进行甲基化和乙酰化。作为验证步骤,核心B将执行
用凝胶迁移率改变分析(EMSA)和染色质研究DNA-蛋白质相互作用
免疫沉淀(CHIP)。此外,核心B将为项目调查人员提供一个特点良好的
ARDS生物库(即来自欧洲血统和非洲血统受试者的DNA),选定的完整列表
每个PPG候选基因的SNPs、中通量基因分型服务和数据分析工具
PPG基因SNPs与VILI/ARDS易感性及严重程度的关系因此,总体来说,核心B
将利用这些技术为所有三个项目提供分子生物学和遗传学研究平台
并产生关于这一PPG研究目标基因的新信息。所有三个项目和
核心D将利用这个集中的核心进行PPG中计划的分子生物学和遗传学分析。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joe G. N. Garcia其他文献
Lysocardiolipin Acyltransferase (lycat) Is A Novel Candidate Gene In Radiation-Induced Pulmonary Fibrosis
溶心磷脂酰基转移酶 (lycat) 是辐射诱发肺纤维化的新候选基因
- DOI:
- 发表时间:
2011 - 期刊:
- 影响因子:0
- 作者:
B. Mathew;Longshuang Huang;I. Noth;Shwu;N. Kaminski;Yutong Zhao;M. Wade;E. Berdyshev;J. Siegler;J. Jacobson;Ralph R. Weishelbaum;V. Natarajan;Joe G. N. Garcia - 通讯作者:
Joe G. N. Garcia
Endothelial cell myosin light chain kinase (MLCK) regulates TNFα‐induced NFκB activity
内皮细胞肌球蛋白轻链激酶 (MLCK) 调节 TNFα 诱导的 NFκB 活性
- DOI:
- 发表时间:
2005 - 期刊:
- 影响因子:0
- 作者:
R. Wadgaonkar;L. Linz;A. Zaiman;Joe G. N. Garcia - 通讯作者:
Joe G. N. Garcia
acute lung injury by simvastatin 4 in the attenuation of murine β Critical role for integrin
辛伐他汀 4 在减弱小鼠β整合素的关键作用中对急性肺损伤的影响
- DOI:
- 发表时间:
2012 - 期刊:
- 影响因子:0
- 作者:
J. Jacobson;Weiguo Chen;S. Sammani;Sumegha Mitra;Shwu;Joe G. N. Garcia - 通讯作者:
Joe G. N. Garcia
Intracellular interaction of myosin light chain kinase with macrophage migration inhibition factor (MIF) in endothelium
肌球蛋白轻链激酶与内皮巨噬细胞迁移抑制因子(MIF)的细胞内相互作用
- DOI:
- 发表时间:
2005 - 期刊:
- 影响因子:4
- 作者:
R. Wadgaonkar;S. Dudek;A. Zaiman;L. Linz;A. Verin;S. Nurmukhambetova;L. Romer;Joe G. N. Garcia - 通讯作者:
Joe G. N. Garcia
American medical education at a crossroads
美国医学教育正处于十字路口
- DOI:
10.1126/scitranslmed.aaa2039 - 发表时间:
2015 - 期刊:
- 影响因子:17.1
- 作者:
A. Feldman;M. Runge;Joe G. N. Garcia;A. Rubenstein - 通讯作者:
A. Rubenstein
Joe G. N. Garcia的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joe G. N. Garcia', 18)}}的其他基金
Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension
治疗肺动脉高压的新型 eNAMPT 中和单克隆抗体的临床前开发
- 批准号:
10723260 - 财政年份:2022
- 资助金额:
$ 22.72万 - 项目类别:
Role of Endothelial eNAMPT Secretion and TLR4 Signaling in the ARDS Vascular Endotype
内皮 eNAMPT 分泌和 TLR4 信号传导在 ARDS 血管内型中的作用
- 批准号:
10440855 - 财政年份:2022
- 资助金额:
$ 22.72万 - 项目类别:
Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension
治疗肺动脉高压的新型 eNAMPT 中和单克隆抗体的临床前开发
- 批准号:
10489982 - 财政年份:2022
- 资助金额:
$ 22.72万 - 项目类别:
Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity
靶向 eNAMPT/TLR4 通路以降低炎症性肠病的严重程度
- 批准号:
10771493 - 财政年份:2022
- 资助金额:
$ 22.72万 - 项目类别:
Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity
靶向 eNAMPT/TLR4 通路以降低炎症性肠病的严重程度
- 批准号:
10602227 - 财政年份:2022
- 资助金额:
$ 22.72万 - 项目类别:
eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis
eNamptorTM:一种降低放射性肺炎和纤维化严重程度的人源化单克隆抗体
- 批准号:
10011266 - 财政年份:2020
- 资助金额:
$ 22.72万 - 项目类别:
eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis
eNamptorTM:一种降低放射性肺炎和纤维化严重程度的人源化单克隆抗体
- 批准号:
10415224 - 财政年份:2020
- 资助金额:
$ 22.72万 - 项目类别:
eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis
eNamptorTM:一种降低放射性肺炎和纤维化严重程度的人源化单克隆抗体
- 批准号:
10274779 - 财政年份:2020
- 资助金额:
$ 22.72万 - 项目类别:
Novel Therapeutic Antibody Targeting of Extracellular NAMPT in Ventilator-Induced Lung Injury (VILI)
呼吸机引起的肺损伤 (VILI) 中细胞外 NAMPT 的新型治疗抗体
- 批准号:
10026453 - 财政年份:2019
- 资助金额:
$ 22.72万 - 项目类别:
Novel Involvement of NAMPT and TLR4 in PAH Vascular Remodeling
NAMPT 和 TLR4 在 PAH 血管重塑中的新参与
- 批准号:
10334432 - 财政年份:2019
- 资助金额:
$ 22.72万 - 项目类别:
相似海外基金
Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
- 批准号:
10648387 - 财政年份:2023
- 资助金额:
$ 22.72万 - 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
- 批准号:
10591804 - 财政年份:2023
- 资助金额:
$ 22.72万 - 项目类别:
MAP2K1 AND MAP2K2 IN ACUTE LUNG INJURY AND RESOLUTION
MAP2K1 和 MAP2K2 在急性肺损伤中的作用及缓解
- 批准号:
10741574 - 财政年份:2023
- 资助金额:
$ 22.72万 - 项目类别:
Lung epithelial cell-derived C3 in acute lung injury
肺上皮细胞衍生的 C3 在急性肺损伤中的作用
- 批准号:
10720687 - 财政年份:2023
- 资助金额:
$ 22.72万 - 项目类别:
Examining the role of TRMT1 and tRNA methylation in acute lung injury and ARDS
检查 TRMT1 和 tRNA 甲基化在急性肺损伤和 ARDS 中的作用
- 批准号:
10719249 - 财政年份:2023
- 资助金额:
$ 22.72万 - 项目类别:
Development of a new treatment for COVID-19-related acute lung injury targeting the microbiota-derived peptide corisin
针对微生物群衍生肽 corisin 开发治疗 COVID-19 相关急性肺损伤的新疗法
- 批准号:
23K07651 - 财政年份:2023
- 资助金额:
$ 22.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Probing immunovascular mechanobiology in pneumonia-associated acute lung injury at the single capillary level
在单毛细血管水平探讨肺炎相关急性肺损伤的免疫血管力学生物学
- 批准号:
10679944 - 财政年份:2023
- 资助金额:
$ 22.72万 - 项目类别:
The amyloid precursor protein protects against acute lung injury
淀粉样前体蛋白可预防急性肺损伤
- 批准号:
10575258 - 财政年份:2023
- 资助金额:
$ 22.72万 - 项目类别:
Role of macrophages and miRNA in regulating lung macrophage polarization and lung pathogenesis during respiratory virus-induced acute lung injury in normal and diabetic Syrian hamsters.
正常和糖尿病叙利亚仓鼠呼吸道病毒引起的急性肺损伤期间巨噬细胞和 miRNA 在调节肺巨噬细胞极化和肺部发病机制中的作用。
- 批准号:
10701207 - 财政年份:2023
- 资助金额:
$ 22.72万 - 项目类别:
Roles of N-glycans on neutrophil beta2 integrins in progression of acute lung injury
N-聚糖对中性粒细胞β2整合素在急性肺损伤进展中的作用
- 批准号:
10837431 - 财政年份:2023
- 资助金额:
$ 22.72万 - 项目类别: